BioWorld

March 28, 2006

Encysive Shares Tumble On FDA Thelin Approvable Letter

Encysive Pharmaceuticals Inc. lost almost half its stock value Monday on news that the FDA may require additional clinical trial work for the pulmonary arterial hypertension drug Thelin. (BioWorld Today) Read More

Corgentech’s Phase II Study With VR1 Agonist Negative

Keryx Pads Balance Sheet With $83M Direct Stock Sale

Systemic RNAi Data Leads To Alnylam Partnership With INEX

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Rare earth: Biomarin to use global reach post-$4.8B Amicus buy

BioWorld

Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...